UNIGE document Scientific Article
previous document  unige:37077  next document
add to browser collection
Title

Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography

Authors
Lencioni, Riccardo
Della Pina, Clotilde
Bruix, Jordi
Grazioli, Luigi
Morana, Giovanni
Filippone, Antonella
Laghi, Andrea
show hidden authors show all authors [1 - 9]
Published in Digestive Diseases and Sciences. 2005, vol. 50, no. 3, p. 533-7
Abstract This study compares ferucarbotran-enhanced magnetic resonance (MR) imaging with spiral computed tomography (CT) in the clinical management of patients with suspected hepatic malignancy. One hundred fifty-nine patients with suspected liver malignancy were included in a prospective, multicenter, phase IIIB clinical trial. Patients were examined with baseline plus contrast-enhanced spiral CT and with baseline plus ferucarbotran-enhanced MR imaging. For each patient, four maps of liver lesions were constructed by a trusted blind party on the basis of (a) baseline plus contrast-enhanced spiral CT, (b) baseline MR imaging, (c) baseline plus ferucarbotran-enhanced MR imaging, and (d) final diagnosis. Three blinded experts evaluated the treatment options for each map. The concordance of the treatment choice based on imaging with the treatment choice based on final diagnosis was verified. The final therapeutic decision was radical therapy for 85 patients, palliative therapy for 49 patients, and no treatment for 25 patients who had a final diagnosis of benign lesion. Proper treatment allocation was achieved in 121 (76%) of 159 patients when the evaluation was based on liver maps obtained from spiral CT, in 97 (61%) of 159 patients when the evaluation was based on liver maps obtained from baseline MR imaging, and in 136 (85%) of 159 patients when the evaluation was based on liver maps obtained from baseline plus ferucarbotran-enhanced MR imaging. MR imaging with ferucabotran was significantly superior to spiral CT for correct treatment allocation (P = 0.0167). Ferucarbotran-enhanced MR imaging is superior to spiral CT in clinical management of patients with suspected hepatic malignancy.
Keywords AdultAgedAged, 80 and overCarcinoma, Hepatocellular/diagnosis/mortality/therapyCombined Modality TherapyContrast MediaDextransFemaleFerrosoferric OxideHumansIron/diagnostic useLiver Neoplasms/diagnosis/mortality/therapyMagnetic Resonance Imaging/methodsMagnetite NanoparticlesMaleMiddle AgedOxides/diagnostic usePrognosisProspective StudiesRadiographic Image EnhancementRisk AssessmentSensitivity and SpecificitySurvival RateTomography, Spiral Computed/methodsTreatment Outcome
Identifiers
PMID: 15810637
Full text
Structures
Research group Hépatologie chirurgicale (327)
Citation
(ISO format)
LENCIONI, Riccardo et al. Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography. In: Digestive Diseases and Sciences, 2005, vol. 50, n° 3, p. 533-7. https://archive-ouverte.unige.ch/unige:37077

198 hits

0 download

Update

Deposited on : 2014-06-03

Export document
Format :
Citation style :